The novel long-acting insulin LY2605541 is superior to insulin glargine in lowering intra-day glucose variability and hypoglycemia event rate from Continuous Glucose Monitoring (C…

Objectives: The basal insulin analog LY2605541 (LY) is PEGylated insulin lispro with a large hydrodynamic size which delays insulin absorption and reduces clearance, resulting in prolonged duration of action. Methodology: Hypoglycemia and glucose variability were assessed with CGM of interstitial glucose (IG) in a subset of patients from a Phase 2, randomized, open-label, parallel study of LY (n = 51) or insulin glargine (GL, n = 25). CGM was conducted on 3 consecutive days (72 – 84 hrs) during the week before Week 0, 6, and 12 study visits. IG intra-patient intra- and inter-day standard deviations (SD) during n…